Associated Press Finance
- Home
- XBIT
XBIT
XBiotech Inc.
as of 03-16-2026 10:38am EST
$2.31
$0.00
0.00%
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 71.3M | IPO Year: | 2015 |
| Target Price: | N/A | AVG Volume (30 days): | 23.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.49 | EPS Growth: | -18.25 |
| 52 Week Low/High: | $2.09 - $3.62 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.83 | Index: | N/A |
| Free Cash Flow: | -40209000.0 | FCF Growth: | N/A |
AI-Powered XBIT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.43%
71.43%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2015 Q2 Q2 2015 Earnings
8-K Jul 29, 2015
2015
Q2
Q2 2015 Earnings
8-KJul 29, 2015
0001171843-15-004162
8-K 1 document.htm
FORM 8-K FILING DOCUMENT
Form 8-K Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 28, 2015
XBIOTECH INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada (State of Incorporation)
001-37347 (Commission File Number)
N/A
8201 E Riverside Dr. Bldg 4, Ste 100 Austin, Texas 78744
(Address of principal executive offices) (Zip Code)
(512) 386-2900 (Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On July 28, 2015, XBiotech Inc. (the "Company"), issued a press release providing a second quarter 2015 corporate and clinical update, which included an update on its cash position as of June 30, 2015. A copy of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On July 28, 2015, XBiotech gave a business update via telephone conference call. An audio webcast of the call can be accessed on the Investors relations section of the XBiotech website at investors.xbiotech.com. The webcast will be archived for 90 days.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
99.1
Press Release of XBiotech Inc., issued July 28, 2015
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
XBIOTECH INC.
(Registrant)
July 29, 2015
(Date)
/s/ JOHN SIMARD
John Simard Chief Executive Officer and President
EXHIBIT INDEX
Exhibit
Number
Description
99.1
Press Release, issued July 28, 2015
Latest XBiotech Inc. News
XBIT Breaking Stock News: Dive into XBIT Ticker-Specific Updates for Smart Investing
Compare XBIT vs Leading Stocks
See how XBIT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XBIT XBiotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.